Kenji Sampei

Title: Kenji Sampei: Innovator in Neurotoxicity Treatment

Introduction

Kenji Sampei is a notable inventor based in Baltimore, MD (US). He has made significant contributions to the field of neurotoxicity treatment through his innovative research and patent.

Latest Patents

Kenji Sampei holds a patent for a method of using selective PARP inhibitors to prevent or treat neurotoxicity. This patent addresses neutral tissue damage resulting from ischemia and reperfusion injury or neurodegenerative diseases. The invention outlines that therapeutically effective amounts of certain selective inhibitors of poly(ADP-ribose) polymerase can be administered through various routes, including intravenously, intraperitoneally, intramuscularly, intraventricularly, or orally. The inhibitors can be provided in the form of capsules or tablets containing single or divided doses. Alternatively, they can be administered as a sterile solution, suspension, or emulsion.

Career Highlights

Kenji Sampei is affiliated with The Johns Hopkins University, where he continues to advance his research in neurotoxicity and related fields. His work has garnered attention for its potential impact on treating neurodegenerative diseases.

Collaborations

Throughout his career, Kenji has collaborated with esteemed colleagues, including Mikael J Eliasson and Allen S Mandir. These collaborations have further enriched his research and contributed to the development of innovative solutions in the medical field.

Conclusion

Kenji Sampei's contributions to the field of neurotoxicity treatment through his patent and research at The Johns Hopkins University highlight his role as a significant innovator. His work has the potential to improve therapeutic strategies for neurodegenerative diseases and enhance patient outcomes.